Julie Milojevic

740 total citations
9 papers, 359 citations indexed

About

Julie Milojevic is a scholar working on Immunology, Hematology and Nephrology. According to data from OpenAlex, Julie Milojevic has authored 9 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 4 papers in Hematology and 3 papers in Nephrology. Recurrent topics in Julie Milojevic's work include Complement system in diseases (4 papers), Platelet Disorders and Treatments (3 papers) and Renal Diseases and Glomerulopathies (3 papers). Julie Milojevic is often cited by papers focused on Complement system in diseases (4 papers), Platelet Disorders and Treatments (3 papers) and Renal Diseases and Glomerulopathies (3 papers). Julie Milojevic collaborates with scholars based in Switzerland, United States and India. Julie Milojevic's co-authors include Andreas Hüser, Frank Wagner, Hermann Gram, G. Junge, Maciej Cabanski, Prasanna Kumar Nidamarthy, Thomas Dörner, Yue Li, Louise Mooney and Olivier Pétricoul and has published in prestigious journals such as Blood, Kidney International and Annals of the Rheumatic Diseases.

In The Last Decade

Julie Milojevic

8 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Milojevic Switzerland	6	157	102	78	67	61	9	359
Veysel Sabri Hançer Türkiye	11	121 0.8×	81 0.8×	18 0.2×	125 1.9×	70 1.1×	47	378
Loren Herrera Hernandez United States	8	44 0.3×	290 2.8×	31 0.4×	42 0.6×	54 0.9×	17	481
Óscar Toldos Spain	10	51 0.3×	115 1.1×	19 0.2×	54 0.8×	37 0.6×	20	347
Sonja Skoupy Austria	10	82 0.5×	54 0.5×	35 0.4×	141 2.1×	95 1.6×	12	368
Jennifer Laskowski United States	13	276 1.8×	168 1.6×	25 0.3×	65 1.0×	18 0.3×	21	437
Eva Jančová Czechia	11	167 1.1×	195 1.9×	35 0.4×	20 0.3×	203 3.3×	23	440
Christian Mrowka Germany	9	97 0.6×	86 0.8×	37 0.5×	28 0.4×	88 1.4×	10	289
Kumiko Shimoyama Japan	11	70 0.4×	15 0.1×	91 1.2×	62 0.9×	92 1.5×	30	342
M. Chen China	9	286 1.8×	184 1.8×	40 0.5×	37 0.6×	64 1.0×	12	478

Countries citing papers authored by Julie Milojevic

Since Specialization

Citations

This map shows the geographic impact of Julie Milojevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Milojevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Milojevic more than expected).

Fields of papers citing papers by Julie Milojevic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Milojevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Milojevic. The network helps show where Julie Milojevic may publish in the future.

Co-authorship network of co-authors of Julie Milojevic

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Milojevic. A scholar is included among the top collaborators of Julie Milojevic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Milojevic. Julie Milojevic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Zhang, Hong, Dana V. Rizk, Vlado Perkovic, et al.. (2023). Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney International. 105(1). 189–199. 62 indexed citations

Risitano, Antonio M., Régis Peffault de Latour, Eng Soo Yap, et al.. (2022). Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy. Blood. 140(Supplement 1). 5803–5804. 2 indexed citations

Risitano, Antonio M., Alexander Röth, Juliette Soret, et al.. (2021). Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. The Lancet Haematology. 8(5). e344–e354. 69 indexed citations

Milojevic, Julie, et al.. (2021). 524 Negative predictive value of PAP smear in patients with leukoplakia patterns on colposcopy. A311.1–A311.

Kazani, Shamsah, David J. Rowlands, Julie Milojevic, et al.. (2020). Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). Journal of Cystic Fibrosis. 20(2). 250–256. 16 indexed citations

Webb, Nicholas J.A., Börje Haraldsson, Anna Schubart, et al.. (2020). MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE. Nephrology Dialysis Transplantation. 35(Supplement_3). 5 indexed citations

Dörner, Thomas, Maximilian Posch, Yue Li, et al.. (2019). Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Annals of the Rheumatic Diseases. 78(5). 641–647. 126 indexed citations

Espié, Pascal, Yanling He, Phillip J. Koo, et al.. (2019). First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody. American Journal of Transplantation. 20(2). 463–473. 68 indexed citations

Bruin, Gerard, И. А. Королева, Julie Milojevic, et al.. (2019). Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis. Clinical Pharmacology & Therapeutics. 106(6). 1380–1388. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact